Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

1.3K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.3K
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

709
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
709
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

906
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
906
Chemical Synapses01:26

Chemical Synapses

8.8K
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
8.8K
Muscle Contraction01:10

Muscle Contraction

6.3K
In skeletal muscles, acetylcholine is released by nerve terminals at the motor endplate—the point of synaptic communication between motor neurons and muscle fibers. The binding of acetylcholine to its receptors on the sarcolemma allows entry of sodium ions into the cell and triggers an action potential in the muscle cell. Thus, electrical signals from the brain are transmitted to the muscle. Subsequently, the enzyme acetylcholinesterase breaks down acetylcholine to prevent excessive...
6.3K
Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

643
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
643

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Consensus Definitions of Disease Activity and Clinical Outcomes in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy.

Neurology·2026
Same author

Burden of Disease in Myasthenia Gravis: A Targeted Literature Review.

Journal of neurology·2026
Same author

Economic Evaluation of Thymectomy for the Treatment of Nonthymomatous Myasthenia Gravis.

JAMA network open·2026
Same author

BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial.

Nature medicine·2026
Same author

Urinary dysfunction in myasthenia Gravis: a cross-sectional case-control study.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2026
Same author

Ocular myasthenia gravis management.

Frontiers in neurology·2025
Same journal

Preface.

Handbook of clinical neurology·2026
Same journal

Foreword.

Handbook of clinical neurology·2026
Same journal

Fundus autofluorescence imaging.

Handbook of clinical neurology·2026
Same journal

The electroretinogram as a means to study the physiology of the retina.

Handbook of clinical neurology·2026
Same journal

Adaptive optics scanning light ophthalmoscopy.

Handbook of clinical neurology·2026
Same journal

Modeling the human retina in a dish: Advances and future directions.

Handbook of clinical neurology·2026
See all related articles

Related Experiment Video

Updated: Jun 15, 2025

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

12.4K

Myasthenia gravis.

Mamatha Pasnoor1, Gil I Wolfe2, Richard J Barohn3

  • 1Department of Neurology, University of Kansas Medical Center, Kansas City, KS, United States.

Handbook of Clinical Neurology
|August 22, 2024
PubMed
Summary
This summary is machine-generated.

Myasthenia gravis (MG) is a rare neuromuscular disorder causing muscle weakness. Research highlights diagnostic antibodies, classification systems, outcome measures, and evolving therapies for MG management.

Keywords:
Acetylcholine receptorAutoimmuneFcRnLRP4MGFAMuscle-specific tyrosine kinaseMyasthenia gravisNeonatal myastheniaNeuromuscular junction

More Related Videos

Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction
11:07

Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction

Published on: April 14, 2022

2.3K
Author Spotlight: Translational Applications of Stimulated SFEMG in Rodent Models
04:30

Author Spotlight: Translational Applications of Stimulated SFEMG in Rodent Models

Published on: March 8, 2024

651

Related Experiment Videos

Last Updated: Jun 15, 2025

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

12.4K
Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction
11:07

Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction

Published on: April 14, 2022

2.3K
Author Spotlight: Translational Applications of Stimulated SFEMG in Rodent Models
04:30

Author Spotlight: Translational Applications of Stimulated SFEMG in Rodent Models

Published on: March 8, 2024

651

Area of Science:

  • Neurology
  • Immunology
  • Genetics

Background:

  • Myasthenia gravis (MG) is a rare neuromuscular junction disorder.
  • Characterized by fatigable muscle weakness, MG presents with diverse clinical manifestations.
  • MG can stem from autoimmune, paraneoplastic, congenital, medication-related causes, or transient neonatal transfer.

Purpose of the Study:

  • To provide an overview of Myasthenia Gravis.
  • To discuss diagnostic advancements, classification, and outcome measures.
  • To review current and emerging therapeutic strategies for MG.

Main Methods:

  • Literature review of MG pathophysiology, diagnosis, and treatment.
  • Analysis of diagnostic antibody testing, including acetylcholine receptor, MuSK, and LRP4 antibodies.
  • Examination of the Myasthenia Gravis Foundation of America (MGFA) classification system and outcome measures.

Main Results:

  • Acetylcholine receptor antibodies are prevalent in MG; MuSK and LRP4 antibodies are also significant diagnostic markers.
  • Validated objective and subjective outcome measures are crucial for clinical trials and research.
  • International consensus guidance for MG management was updated in 2020, reflecting advancements in care.

Conclusions:

  • MG diagnosis and management have advanced with the discovery of new antibodies and standardized approaches.
  • Therapeutic options for MG are expanding, with novel mechanistic therapies under investigation.
  • Continued research and updated clinical guidelines are essential for optimizing patient outcomes in Myasthenia Gravis.